Company Description
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies.
The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors.
Its immunotherapy programs include AN8025, a tri-functional fusion protein (αPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor.
The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China.
Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026.
Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.
| Country | Singapore |
| Founded | 2004 |
| IPO Date | Sep 29, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Yang Lu |
Contact Details
Address: 77 Robinson Road, 2nd floor Singapore, 068896 Singapore | |
| Phone | 848 230 7430 |
| Website | adlainortye.com |
Stock Details
| Ticker Symbol | ANL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 1944552 |
| CUSIP Number | 00704R109 |
| ISIN Number | US00704R1095 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yang Lu EMBA | Co- Founder, Chief Executive Officer and Chairman |
| Dr. Ngai Chiu Tse M.D., Ph.D. | President and Head of Research & Development |
| Dr. Xiaofeng Ye Ph.D. | Chief Financial Officer |
| Dr. Zhiyong Yu Ph.D. | Vice President of Operations |
| Chen Yang EMBA | Head of Human Resources and Administration & Government Affairs |
| Donghui Yang | Chairman of the Greater China Region |
| Dr. Nanhai He Ph.D. | Head of Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 15, 2026 | EFFECT | Notice of Effectiveness |
| Sep 11, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 11, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 11, 2026 | POS AM | Post-Effective amendments for registration statement |
| Sep 8, 2026 | 6-K | Report of foreign issuer |
| Aug 26, 2026 | 6-K | Report of foreign issuer |
| Aug 19, 2026 | 6-K | Report of foreign issuer |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 14, 2026 | 6-K | Report of foreign issuer |